Long-term Jakafi exposure increases non-melanoma skin cancer and shingles risk in myelofibrosis patients. Short-term Jakafi exposure is linked to higher pneumonia, sepsis, and urinary tract infection ...

For patients with myelofibrosis who had anemia at diagnosis and received erythropoiesis-stimulating agents (ESAs) or danazol ...

The iRR6 model refines risk stratification for intermediate-1 myelofibrosis patients, incorporating ruxolitinib dosing, spleen reduction, and transfusion needs. Validation in an external cohort ...

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis. Watch part 1 to ...

JAK inhibitors have a proven survival advantage, but they're not curative. What might the future hold in terms of treating the long-term disease course? Dr. Bose from The University of Texas MD ...

Syntara has reported "outstanding" results for its ongoing myelofibrosis trial, raising hopes for sufferers of the rare blood cancer.